Exelixis
EXEL
#1660
Rank
NZ$17.33 B
Marketcap
$60.70
Share price
1.26%
Change (1 day)
73.03%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Cash on Hand

Cash on Hand as of September 2024 : NZ$1.99 Billion

According to Exelixis's latest financial reports the company has NZ$1.99 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Exelixis - Cash on Hand chart (from 2000 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31NZ$1.57 B-23.63%
2022-12-31NZ$2.06 B-4.05%
2021-12-31NZ$2.14 B28.45%
2020-12-31NZ$1.67 B32.14%
2019-12-31NZ$1.26 B22.43%
2018-12-31NZ$1.03 B89.31%
2017-12-31NZ$0.54 B-9.91%
2016-12-31NZ$0.60 B148.29%
2015-12-31NZ$0.24 B32.55%
2014-12-31NZ$0.18 B-37.58%
2013-12-31NZ$0.29 B-41.01%
2012-12-31NZ$0.50 B100.94%
2011-12-31NZ$0.24 B18.05%
2010-12-31NZ$0.21 B-24.59%
2009-12-31NZ$0.27 B-38.16%
2008-12-31NZ$0.45 B27.55%
2007-12-31NZ$0.35 B39.61%
2006-12-31NZ$0.25 B16.76%
2005-12-31NZ$0.21 B-0.01%
2004-12-31NZ$0.21 B-40.37%
2003-12-31NZ$0.36 B-14.01%
2002-12-31NZ$0.42 B-22.65%
2001-12-31NZ$0.54 B115.9%
2000-12-31NZ$0.25 B1823.63%
1999-12-31NZ$13.2 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
NZ$7.19 B 261.49%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$12.19 B 512.54%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$19.01 B 854.79%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$13.55 B 580.65%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$15.08 B 657.76%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$33.98 B 1,606.84%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$11.89 B 497.14%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$47.48 M-97.62%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.12 B-93.49%๐Ÿ‡บ๐Ÿ‡ธ USA